Summit Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| SUMMIT THERAPEUTICS INC. | |
|---|---|
| By: | /s/ Robert W. Duggan |
| Name:Title: | Robert W. DugganChief Executive Officer and Executive Chairman; Principal Executive Officer |
| By: | /s/ Mahkam Zanganeh |
| Name:Title: | Dr. Mahkam ZanganehChief Executive Officer, President and member of the Board; Principal Executive Officer |
| By: | /s/ Ankur Dhingra |
| Name:Title: | Ankur DhingraChief Financial Officer; Principal Financial Officer |
Date: February 20, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Robert W. Duggan | Chief Executive Officer and Executive Chairman (Principal Executive Officer) | February 18, 2024 |
| Robert W. Duggan | ||
| /s/ Mahkam Zanganeh | Chief Executive Officer, President and Director(Principal Executive Officer) | February 18, 2024 |
| Dr. Mahkam Zanganeh | ||
| /s/ Manmeet Soni | Chief Operating Officer and Director | February 18, 2024 |
| Manmeet Soni | ||
| /s/ Ankur Dhingra | Chief Financial Officer(Principal Financial Officer) | February 18, 2024 |
| Ankur Dhingra | ||
| /s/ Robert F. Booth | Director | February 16, 2024 |
| Dr. Robert F. Booth | ||
| /s/ Alessandra Cesano | Director | February 16, 2024 |
| Dr. Alessandra Cesano | ||
| /s/ Kenneth Clark | Director | February 16, 2024 |
| Kenneth Clark | ||
| /s/ Ujwala Mahatme | Director | February 18, 2024 |
| Ujwala Mahatme | ||
| /s/ Yu Xia | Director | February 18, 2024 |
| Dr. Yu Xia | ||
| Summit Therapeutics Inc. | Page |
|---|---|
| Index to the Financial Statements | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 106 |
| Consolidated Balance Sheets | 108 |
| Consolidated Statements of Operations and Comprehensive Loss | 109 |
| Consolidated Statements of Stockholders’ Equity | 110 |
| Consolidated Statements of Cash Flows | 111 |
| Notes to the Consolidated Financial Statements | 112 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.